NP 108
Alternative Names: NP-108Latest Information Update: 31 Mar 2023
Price :
$50 *
At a glance
- Originator NovaBiotics
- Class Antibacterials; Antifungals; Peptides; Skin disorder therapies
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Skin disorders
Most Recent Events
- 30 Mar 2023 Preclinical trials in Skin disorders in United Kingdom (Topical) (NovaBiotics pipeline, March 2023)